2 years ago
FATE
AnalystsRobert BurnsRobert Burns's Stock Forecasts
AnalystsRobert Burns
Sectors:
Industries:
Analyst Ranking
Bottom 1%
#4866 out of 4868 analysts
Average Return
-20.9%
Win Rate
27%127 out of 470
Risk vs Reward
Poor
Good
Robert Burns's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Immunomedics IncIMMU | +342.36% | $18.91 | $83.65 | 2020-04-06 - 2020-09-14 | Buy |
Adc Therapeutics SaADCT | +287.50% | $0.80 | $3.10 | 2023-09-18 - 2024-09-18 | Buy |
Turning Point Therapeutics IncTPTX | +208.74% | $35.13 | $108.46 | 2020-03-16 - 2021-03-17 | Buy |
Revolution Medicines IncRVMD | +201.93% | $19.65 | $59.33 | 2023-11-13 - 2024-11-12 | Buy |
Adc Therapeutics SaADCT | +190.14% | $0.71 | $2.06 | 2023-11-19 - 2024-11-19 | Buy |
Robert Burns Analyst Color
Get additional color on Robert Burns's coverage of popular stocks
Robert Burns's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Springworks Therapeutics IncSWTX | 29 | Hold | $47.00 | +1.51% | Downgrades | 21 hours ago |
Caribou Biosciences IncCRBU | 14 | Buy | $3.00 | +252.53% | Maintains | 3 days ago |
Tango Therapeutics IncTNGX | 12 | Buy | $13.00 | +821.99% | Reiterates | 17 days ago |
Prelude Therapeutics IncPRLD | 15 | Buy | $5.00 | +420.83% | Reiterates | 23 days ago |
Bicara Therapeutics IncBCAX | 3 | Buy | $44.00 | +206.19% | Maintains | 24 days ago |
Tuhura Biosciences IncHURA | 2 | Buy | $12.00 | +217.46% | Maintains | a month ago |
Nurix Therapeutics IncNRIX | 15 | Buy | $36.00 | +212.23% | Reiterates | a month ago |
Elicio Therapeutics IncELTX | 7 | Buy | $10.00 | +103.25% | Reiterates | a month ago |
Biontech SeBNTX | 36 | Buy | $145.00 | +39.22% | Maintains | a month ago |
Adc Therapeutics SaADCT | 18 | Buy | $8.00 | +459.44% | Reiterates | a month ago |
Perspective Therapeutics IncCATX | 3 | Buy | $10.00 | +308.16% | Reiterates | a month ago |
Exelixis IncEXEL | 7 | Buy | $40.00 | +2.17% | Reiterates | a month ago |
Macrogenics IncMGNX | 18 | Hold | $2.00 | +15.27% | Maintains | a month ago |
Y Mabs Therapeutics IncYMAB | 13 | Buy | $12.00 | +182.35% | Maintains | a month ago |
Enliven Therapeutics IncELVN | 3 | Buy | $39.00 | +105.91% | Maintains | a month ago |
Pmv Pharmaceuticals IncPMVP | 11 | Buy | $5.00 | +405.05% | Reiterates | a month ago |
Allogene Therapeutics IncALLO | 14 | Buy | $8.00 | +376.19% | Maintains | a month ago |
Black Diamond Therapeutics IncBDTX | 13 | Buy | $12.00 | +605.88% | Maintains | a month ago |
Onkure Therapeutics IncOKUR | 3 | Buy | $34.00 | +1,265.46% | Maintains | a month ago |
Zymeworks IncZYME | 20 | Hold | $13.00 | -0.08% | Maintains | 2 months ago |
Nuvation Bio IncNUVB | 14 | Buy | $10.00 | +344.44% | Maintains | 2 months ago |
Repare Therapeutics IncRPTX | 18 | Buy | $5.00 | +264.96% | Maintains | 2 months ago |
Relay Therapeutics IncRLAY | 20 | Buy | $16.00 | +380.48% | Reiterates | 2 months ago |
Arrivent Biopharma IncAVBP | 8 | Buy | $39.00 | +83.44% | Reiterates | 2 months ago |
Revolution Medicines IncRVMD | 17 | Buy | $73.00 | +80.78% | Maintains | 2 months ago |
Cardiff Oncology IncCRDF | 1 | Buy | $17.00 | +520.44% | Maintains | 2 months ago |
Oric Pharmaceuticals IncORIC | 22 | Buy | $21.00 | +267.78% | Reiterates | 2 months ago |
Replimune Group IncREPL | 15 | Buy | $22.00 | +124.95% | Maintains | 3 months ago |
IMMIX Biopharma IncIMMX | 7 | Buy | $7.00 | +231.75% | Reiterates | 3 months ago |
Cogent Biosciences IncCOGT | 9 | Buy | $14.00 | +168.71% | Maintains | 4 months ago |
Cargo Therapeutics IncCRGX | 3 | Buy | $33.00 | +622.10% | Reiterates | 6 months ago |
Igm Biosciences IncIGMS | 13 | Hold | $11.00 | +694.22% | Maintains | 8 months ago |
Kronos Bio IncKRON | 10 | Buy | $2.25 | +151.96% | Reiterates | 8 months ago |
Omega Therapeutics IncOMGAQ | 9 | Buy | $12.00 | +8,291.61% | Reiterates | 9 months ago |
Apollomics IncAPLM | 5 | Buy | $200.00 | +2,934.90% | Maintains | a year ago |
Viracta Therapeutics IncVIRX | 8 | Buy | $4.00 | N/A | Reiterates | a year ago |
Effector Therapeutics IncEFTR | 3 | Buy | $24.00 | N/A | Reiterates | a year ago |
Calidi Biotherapeutics IncCLDI | 2 | Buy | $20.00 | N/A | Maintains | a year ago |
Kineta IncKANT | 4 | Buy | $8.00 | N/A | Reiterates | a year ago |
Portage Biotech IncPRTG | 5 | Buy | $120.00 | N/A | Maintains | a year ago |
Whitehawk Therapeutics IncWHWK | 9 | Buy | $36.00 | N/A | Maintains | a year ago |
Kinnate Biopharma IncKNTE | 6 | Buy | $24.00 | N/A | Reiterates | 2 years ago |
Gt Biopharma IncGTBP | 6 | Buy | $150.00 | N/A | Reiterates | 2 years ago |
Atara Biotherapeutics IncATRA | 8 | Buy | $700.00 | N/A | Maintains | 2 years ago |
Ikena Oncology IncIKNA | 4 | Buy | $22.00 | N/A | Reiterates | 2 years ago |
Fate Therapeutics IncFATE | 6 | Hold | $7.00 | N/A | Downgrades | 2 years ago |
Tcr2 Therapeutics IncTCRR | 4 | Buy | $13.00 | N/A | Maintains | 2 years ago |
Neurogene IncNGNE | 3 | Hold | N/A | N/A | Downgrades | 2 years ago |
Forma Therapeutics Holdings IncFMTX | 2 | Hold | $20.00 | N/A | Downgrades | 3 years ago |
Turning Point Therapeutics IncTPTX | 6 | Hold | $76.00 | N/A | Downgrades | 3 years ago |
Cytomx Therapeutics IncCTMX | 1 | Buy | $11.00 | N/A | Maintains | 3 years ago |
Nucana PLCNCNA | 7 | Buy | $225.00 | N/A | Maintains | 3 years ago |
Molecular Partners AgMOLN | 1 | Buy | $25.00 | N/A | Assumes | 4 years ago |
Autolus Therapeutics PLCAUTL | 1 | Buy | $13.00 | N/A | Maintains | 4 years ago |
Immunomedics IncIMMU | 4 | Hold | $88.00 | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.